TABLE 2.

Summary of the results.

Parameter	Figure	5 Res	10 Res	15 Res	W/D 20 days
Catalepsy duration	2	ns	↑	↑	ns
Tyrosine Hydroxylase/SNpc (IH)	3	ns	↑	↑	ns
GFAP/DS (IH)	4	ns	ns	↑	ns
GFAP/SNpc (IH)	4	ns	↑	↑	↑
IBA 1/DS (IH)	5	↑	↑	ni	↑
IBA 1/SNpc (IH)	5	ns	↑	ni	ns
CD11b/DS (IH)	6	↑	ni	ns	↑
CD11b/SNpc (IH)	6	↑	ni	↑	↑
CD11b + iNOS/DS (IF)	7	ns	ni	↑	ns
CD11b + iNOS/SNpc (IF)	7	ns	ni	↑	ns
CD11b + Arg I/DS (IF)	8	ns	ni	ns	↑
CD11b + Arg I/SNpc (IF)	8	ns	ni	ns	↑
TNF-α/DS (RTPCR)	9	ns	↑	ni	ns
IL-1β/DS (RTPCR)	9	ns	ns	ni	ns
IL-10/DS (RTPCR)	9	ns	ns	ni	↑
α-synuclein/DS (IH)	Suppl.	↑	↑	ni	↑
α-synuclein/SNpc (IH)	Suppl.	↑	↑	ni	ns

Outcomes after 5, 10, or 15 injections of reserpine (Res) or after 20 days of treatment withdrawal (W/D 20 days) compared to vehicle-treated groups.↑, increase; ↓, decrease; ns, no significant effect; ni, not included in the analysis; DS, dorsal striatum; SNpc, substantia nigra pars compacta; IH, immunohistochemistry assay; IF, immunofluorescence assay.